Top Markets
#1 MowCat MowCat +779.10%
#2 龙虾 (Lobster) 龙虾 (Lobster) +86.95%
#3 Akedo Akedo +39.07%
#4 Magma Finance Magma Finance +38.31%
#5 MarsCoin MarsCoin +31.11%
#6 SIXSEVEN SIXSEVEN +30.85%
#7 Cortex Cortex +25.84%
#8 DeXe DeXe +19.90%
#9 Pons Pons +15.40%
#10 OpenEden OpenEden +14.56%
Coin of the day
MowCat MowCat
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204
Clasificación en acciones #7952
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical... Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Precio por acción
$3.11
Capitalización bursátil
$1.41B
Cambio (1 día)
-1.97%
Cambio (1 año)
-57.22%
País
CN
Comercio Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)

Categoría

Healthcare
Ganancias de Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Staidson (Beijing) BioPharmaceuticals Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Staidson (Beijing) BioPharmaceuticals Co., Ltd. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH